Takeda/Ovid Plan Phase III For Soticlestat In Dravet Syndrome, But Pull Back On LGS

A Phase II trial testing Takeda Pharmaceutical Company Limited. and Ovid Therapeutics, Inc.'s first-in-class enzyme cholesterol 24-hydroxylase (CH24H) inhibitor soticlestat in children with the rare developmental and epileptic encephalopathies (DEEs) Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) has yielded mixed results, so the partners are moving forward with a Phase III trial in DS but pulling back on LGS to further analyze the results.

Takeda and Ovid announced the top-line data from the Phase II ELEKTRA study on 25 August, with the trial meeting the primary endpoint: a statistically significant reduction of seizures from baseline compared to placebo in the maintenance period for the combined DS and LGS study population